Chardan Capital Maintains Buy on iBio, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Keay Nakae maintains a Buy rating on iBio (AMEX:IBIO) and keeps the price target at $5.
June 03, 2024 | 7:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital analyst Keay Nakae maintains a Buy rating on iBio and keeps the price target at $5.
The reaffirmation of a Buy rating and a $5 price target by Chardan Capital is likely to positively impact iBio's stock price in the short term as it reinforces investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100